A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Eligibility Criteria
2.2. Literature Search and Study Selection
2.3. Data Collection and Presentation
2.4. Data Summary, Synthesis, and Meta-Analysis
Author [Ref. No.] | Year | Study Type | Study Period | Follow-Up Period (Years) | Patients with Localized DDCS (N) | Surgery + NAC Group (N) | Surgery + NAC Group: 5-Year Survival (N) | SA Group (N) | SA Group: 5-Year Survival (N) |
---|---|---|---|---|---|---|---|---|---|
Bui et al. [28] | 2023 | MR | 2004–2022 | Median: 1 | 47 | 12 | 3 | 35 | 14 |
Davies et al. [37] | 2014 | SR | NR | NR | 2 | 1 | 0 | 1 | 0 |
Dickey et al. [25] | 2004 | SR | 1986–2000 | Min.: 2 | 37 | 22 | 1 | 15 | 2 |
Frassica et al. [12] | 1986 | SR | 1915–1983 | Min.: 2 | 50 | 9 | 2 | 41 | 4 |
Grimer et al. [10] | 2007 | MR | 1975–2005 | NR | 242 | 76 | 25 | 166 | 42 |
Johnson et al. [38] | 1986 | MR | 1948–1985 | Mean: 1.3 | 15 | 2 | 0 | 13 | 2 |
Kozawa et al. [27] | 2022 | MR | 1990–2014 | Mean: 2.3 | 40 | 14 | 4 | 26 | 7 |
Liu et al. [24] | 2017 | SR | 2008–2015 | Mean: 1.2 | 14 | 5 | 0 | 9 | 2 |
Mitchell et al. [11] | 2000 | SR | Since 1977 | Mean: 1.8 | 16 | 10 | 4 | 6 | 0 |
Staals et al. [8] | 2006 | SR | 1969–2003 | Mean: 2.8 | 82 | 24 | 7 | 58 | 17 |
Staals et al. [9] | 2007 | SR | 1970–2002 | Median: 1.2 | 11 | 6 | 5 | 5 | 0 |
Author [Ref. No.] | Male (%) | Mean Age (Years) | Tumors Located in the Trunk (%) | Mean Tumor Size (cm) | Radiographic Subtype | PathologiCal Fracture (%) | Patients with R0 Surgical Margin (%) | Patients Who Received Adjuvant RT | Mean Dedifferentiated Area (%) | CTX Regimen | Histologic Response Assessment: Preoperative CTX |
---|---|---|---|---|---|---|---|---|---|---|---|
Bui et al. [28] | NR | NR | NR | NR | NR | NR | NR | NR | NR | MAP, IFO | NR |
Davies et al. [37] | 0% vs. 100% | 47 vs. 43 | 100% vs. 100% | NR | NR | NR | 0% vs. 0% | 0% vs. 0% | NR | NR | NR |
Dickey et al. [25] | 60% vs. 55% | 60 vs. 69 | NR | 9.6 vs. 10.3 | NR | NR | 86% vs. 100% | 0% vs. 0% | NR | MAP, IFO | NR |
Frassica et al. [12] | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Grimer et al. [10] | NR | NR | NR | NR | NR | NR | NR | NR | NR | AP, AI | ≥90% necrosis: 15% |
Johnson et al. [38] | 50% vs. 69% | 54 vs. 56 | 50% vs. 54% | NR | NR | NR | 100% vs. 69% | 0% vs. 15% | NR | CYC, DOX, VCR, DTIC, CDDP, MTX | NR |
Kozawa et al. [27] | NR | NR | NR | NR | NR | NR | 100% vs. 100% | NR | NR | NR | NR |
Liu et al. [24] | 40% vs. 56% | 52 vs. 46 | 60% vs. 56% | NR | NR | NR | 80% vs. 78% | NR | NR | CDDP, EPR, IFO | NR |
Mitchell et al. [11] | 70% vs. 67% | 47 vs. 75 | 40% vs. 17% | NR | Peripheral: 30%, Central: 70% vs. Peripheral: 25%, Central: 75% | 10% vs. 17% | 100% vs. 100% | 0% vs. 0% | NR | AP, VCR | ≥90% necrosis: 20% |
Staals et al. [8] | NR | * | NR | n.s. | All central | NR | n.s. | NR | n.s. | MAP, IFO | ≥90% necrosis: 0% |
Staals et al. [9] | NR | n.s. | n.s. | n.s. | All peripheral | NR | NR | NR | 52% vs. 76% | MAP, IFO | NR |
2.5. Assessment of Methodological Quality
2.6. Search Results
2.7. Demographic Data and Proportion of Patients Treated with Surgery + NAC or SA
2.8. Methodological Quality of Included Studies
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Inwards, C.Y.; Bloem, J.L.; Hogendoorn, P.C.W. Dedifferentiated chondrosarcoma. In WHO Classification of Tumours, 5th ed.; Soft Tissue and Bone Tumours. The WHO Classification of Tumours Editorial Board; International Arctic Research Center: Lyon, France, 2020; pp. 388–390. [Google Scholar]
- Ogura, K.; Higashi, T.; Kawai, A. Statistics of bone sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. J. Orthop. Sci. 2017, 22, 133–143. [Google Scholar] [CrossRef] [PubMed]
- Hua, K.C.; Hu, Y.C. Treatment method and prognostic factors of chondrosarcoma: Based on Surveillance, Epidemiology, and End Results (SEER) database. Transl. Cancer Res. 2020, 9, 4250–4266. [Google Scholar] [CrossRef] [PubMed]
- Mercuri, M.; Picci, P.; Campanacci, L.; Rulli, E. Dedifferentiated chondrosarcoma. Skeletal Radiol. 1995, 24, 409–416. [Google Scholar] [CrossRef] [PubMed]
- Bertoni, F.; Present, D.; Bacchini, P.; Picci, P.; Pignatti, G.; Gherlinzoni, F.; Campanacci, M. Dedifferentiated peripheral chondrosarcomas. A report of seven cases. Cancer 1989, 63, 2054–2059. [Google Scholar] [CrossRef] [PubMed]
- Henderson, E.R.; Pala, E.; Angelini, A.; Rimondi, E.; Ruggieri, P. Dedifferentiated peripheral chondrosarcoma: A review of radiologic characteristics. Sarcoma 2013, 2013, 505321. [Google Scholar] [CrossRef] [PubMed]
- Amary, M.F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; O’Donnell, P.; Grigoriadis, A.; Diss, T.; et al. IDH1 and IDH2 Mutations Are Frequent Events in Central Chondrosarcoma and Central and Periosteal Chondromas but Not in Other Mesenchymal Tumours. J. Pathol. 2011, 224, 334–343. [Google Scholar] [CrossRef] [PubMed]
- Staals, E.L.; Bacchini, P.; Bertoni, F. Dedifferentiated central chondrosarcoma. Cancer 2006, 106, 2682–2691. [Google Scholar] [CrossRef]
- Staals, E.L.; Bacchini, P.; Mercuri, M.; Bertoni, F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J. Bone Jt. Surg. Am. 2007, 89, 987–993. [Google Scholar] [CrossRef]
- Grimer, R.J.; Gosheger, G.; Taminiau, A.; Biau, D.; Matejovsky, Z.; Kollender, Y.; San-Julian, M.; Gherlinzoni, F.; Ferrari, C. Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. Eur. J. Cancer 2007, 43, 2060–2065. [Google Scholar] [CrossRef]
- Mitchell, A.D.; Ayoub, K.; Mangham, D.C.; Grimer, R.J.; Carter, S.R.; Tillman, R.M. Experience in the treatment of dedifferentiated chondrosarcoma. J. Bone Jt. Surg. Br. 2000, 82, 55–61. [Google Scholar] [CrossRef]
- Frassica, F.J.; Unni, K.K.; Beabout, J.W.; Sim, F.H. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J. Bone Jt. Surg. Am. 1986, 68, 1197–1205. [Google Scholar] [CrossRef] [PubMed]
- Sopta, J.; Dordević, A.; Tulić, G.; Mijucić, V. Dedifferentiated chondrosarcoma: Our clinico-pathological experience and dilemmas in 25 cases. J. Cancer Res. Clin. Oncol. 2008, 134, 147–152. [Google Scholar] [CrossRef] [PubMed]
- Nemecek, E.; Funovics, P.T.; Hobusch, G.M.; Lang, S.; Willegger, M.; Sevelda, F.; Brodowicz, T.; Stihsen, C.; Windhager, R.; Panotopoulos, J. C-reactive protein: An independent predictor for dedifferentiated chondrosarcoma. J. Orthop. Res. 2018, 36, 2797–2801. [Google Scholar] [CrossRef]
- Miao, R.; Choy, E.; Raskin, K.A.; Schwab, J.H.; Nielsen, G.P.; Deshpande, V.; Chebib, I.; DeLaney, T.F.; Hornicek, F.J.; Cote, G.M.; et al. Prognostic factors in dedifferentiated chondrosarcoma: A retrospective analysis of a large series treated at a single institution. Sarcoma 2019, 2019, 9069272. [Google Scholar] [CrossRef] [PubMed]
- Strotman, P.K.; Reif, T.J.; Kliethermes, S.A.; Sandhu, J.K.; Nystrom, L.M. Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001–2011). J. Surg. Oncol. 2017, 116, 252–257. [Google Scholar] [CrossRef] [PubMed]
- Amer, K.M.; Munn, M.; Congiusta, D.; Abraham, J.A.; Basu Mallick, A. Survival and prognosis of chondrosarcoma subtypes: SEER database analysis. J. Orthop. Res. 2020, 38, 311–319. [Google Scholar] [CrossRef] [PubMed]
- Dahlin, D.C.; Beabout, J.W. Dedifferentiation of low-grade chondrosarcomas. Cancer 1971, 28, 461–466. [Google Scholar] [CrossRef]
- Gong, L.H.; Su, Y.B.; Zhang, W.; Liu, W.F.; Dong, R.F.; Sun, X.Q.; Zhang, M.; Ding, Y. Dedifferentiated central chondrosarcoma: A clinical, histopathological, and immunohistochemical analysis of 57 cases. Front. Med. 2021, 8, 746909. [Google Scholar] [CrossRef]
- Meijer, D.; de Jong, D.; Pansuriya, T.C.; van den Akker, B.E.; Picci, P.; Szuhai, K.; Bovée, J.V.G.M. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 2012, 51, 899–909. [Google Scholar] [CrossRef]
- Chen, S.; Fritchie, K.; Wei, S.; Ali, N.; Curless, K.; Shen, T.; Brini, A.T.; Latif, F.; Sumathi, V.; Siegal, G.P.; et al. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Hum. Pathol. 2017, 65, 239–246. [Google Scholar] [CrossRef]
- Lucas, C.H.G.; Grenert, J.P.; Horvai, A. Targeted next-generation sequencing identifies molecular and genetic events in dedifferentiated chondrosarcoma. Arch. Pathol. Lab. Med. 2021, 145, 1009–1017. [Google Scholar] [CrossRef]
- Kawaguchi, S.; Sun, T.; Lin, P.P.; Deavers, M.; Harun, N.; Lewis, V.O. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin. Orthop. Relat. Res. 2014, 472, 983–989. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Xi, Y.; Li, M.; Jiao, Q.; Zhang, H.; Yang, Q.; Yao, W. Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients. PLoS ONE 2017, 12, e0173665. [Google Scholar] [CrossRef] [PubMed]
- Dickey, I.D.; Rose, P.S.; Fuchs, B.; Wold, L.E.; Okuno, S.H.; Sim, F.H.; Scully, S.P. Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes. J. Bone Jt. Surg. Am. 2004, 86, 2412–2418. [Google Scholar] [CrossRef] [PubMed]
- Sambri, A.; Tuzzato, G.; Donati, D.M.; De Paolis, M.; Bianchi, G. Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs. J. Orthop. Sci. 2021, 26, 473–477. [Google Scholar] [CrossRef] [PubMed]
- Kozawa, E.; Nishida, Y.; Kawai, A.; Hayakawa, K.; Setsu, N.; Kawashima, H.; Iwata, S.; Tsuchiya, H.; Tsukushi, S.; Takenaka, S.; et al. Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: A multi-institutional study. Cancer Sci. 2022, 113, 2397–2408. [Google Scholar] [CrossRef] [PubMed]
- Bui, N.; Dietz, H.; Farag, S.; Hirbe, A.C.; Wagner, M.J.; Van Tine, B.A.; Ganjoo, K.; Jones, R.L.; Keedy, V.L.; Davis, E.J. A retrospective multi-institutional cohort analysis of clinical characteristics and outcomes in dedifferentiated chondrosarcoma. Cancers 2023, 15, 2617. [Google Scholar] [CrossRef] [PubMed]
- Cranmer, L.D.; Chau, B.; Mantilla, J.G.; Loggers, E.T.; Pollack, S.M.; Kim, T.S.; Kim, E.Y.; Kane, G.M.; Thompson, M.J.; Harwood, J.L.; et al. Is chemotherapy associated with improved overall survival in patients with dedifferentiated chondrosarcoma? A SEER database analysis. Clin. Orthop. Relat. Res. 2022, 480, 748–758. [Google Scholar] [CrossRef]
- Gonzalez, M.R.; Bryce-Alberti, M.; Portmann-Baracco, A.; Inchaustegui, M.L.; Castillo-Flores, S.; Pretell-Mazzini, J. Appendicular dedifferentiated chondrosarcoma: A management and survival study from the SEER database. J. Bone Oncol. 2022, 37, 100456. [Google Scholar] [CrossRef]
- Hompland, I.; Ferrari, S.; Bielack, S.; Palmerini, E.; Hall, K.S.; Picci, P.; Hecker-Nolting, S.; Donati, D.M.; Blattmann, C.; Bjerkehagen, B.; et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. Eur. J. Cancer 2021, 151, 150–158. [Google Scholar] [CrossRef]
- Biermann, J.S.; Chow, W.; Reed, D.R.; Lucas, D.; Adkins, D.R.; Agulnik, M.; Benjamin, R.S.; Brigman, B.; Budd, G.T.; Curry, W.T.; et al. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J. Natl. Compr. Canc. Netw. 2017, 15, 155–167. [Google Scholar] [CrossRef] [PubMed]
- Strauss, S.J.; Frezza, A.M.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bolle, S.; Bonvalot, S.; et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2021, 32, 1520–1536. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
- Cochrane Handbook for Systematic Reviews of Interventions. Available online: https://training.cochrane.org/handbook (accessed on 10 October 2023).
- ProMeta 3—IDoStatistics. Available online: https://idostatistics.com/prometa3/ (accessed on 16 May 2023).
- Davies, B.W.; Prescott, C.R.; Said, S.A.; Campana, J.; Attié-Castro, F.A.; Velasco E Cruz, A.A.; Durairaj, V.D. Radiation-induced dedifferentiated chondrosarcoma with orbital invasion. Ophthalmic Plast. Reconstr. Surg. 2014, 30, 205–208. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.; Têtu, B.; Ayala, A.G.; Chawla, S.P. Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. Cancer 1986, 58, 278–286. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.Y.; Park, J.E.; Lee, Y.J.; Seo, H.J.; Sheen, S.S.; Hahn, S.; Jang, B.H.; Son, H.J. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J. Clin. Epidemiol. 2013, 66, 408–414. [Google Scholar] [CrossRef] [PubMed]
- Nooij, M.A.; Whelan, J.; Bramwell, V.H.C.; Taminiau, A.T.; Cannon, S.; Hogendoorn, P.C.W.; Pringle, J.; Uscinska, B.M.; Weeden, S.; Kirkpatrick, A.; et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: A European Osteosarcoma Intergroup Study. Eur. J. Cancer 2005, 41, 225–230. [Google Scholar] [CrossRef]
- Bielack, S.S.; Smeland, S.; Whelan, J.S.; Marina, N.; Jovic, G.; Hook, J.M.; Krailo, M.D.; Gebhardt, M.; Pápai, Z.; Meyer, J.; et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. J. Clin. Oncol. 2015, 33, 2279–2287. [Google Scholar] [CrossRef]
- Italiano, A.; Mir, O.; Cioffi, A.; Palmerini, E.; Piperno-Neumann, S.; Perrin, C.; Chaigneau, L.; Penel, N.; Duffaud, F.; Kurtz, J.E.; et al. Advanced chondrosarcomas: Role of chemotherapy and survival. Ann. Oncol. 2013, 24, 2916–2922. [Google Scholar] [CrossRef]
- Albergo, J.I.; Gaston, C.L.; Jeys, L.M.; Khajuria, A.; Carter, S.R.; Tillman, R.M.; Abudu, A.T.; Grimer, R.J. Management and prognostic significance of pathological fractures through chondrosarcoma of the femur. Int. Orthop. 2015, 39, 943–946. [Google Scholar] [CrossRef]
- Gronchi, A.; Miah, A.B.; Dei Tos, A.P.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bolle, S.; et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann. Oncol. 2021, 32, 1348–1365. [Google Scholar] [CrossRef] [PubMed]
- Dehner, C.A.; Maloney, N.; Amini, B.; Jennings, J.W.; McDonald, D.J.; Wang, W.L.; Chrisinger, J.S.A. Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component. Mod. Pathol. 2022, 35, 922–928. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Lin, P.C.; Zhou, B.P. Inflammation fuels tumor progress and metastasis. Curr. Pharm. Des. 2015, 21, 3032–3040. [Google Scholar] [CrossRef] [PubMed]
- Scholte, C.H.J.; Dorleijn, D.M.J.; Krijvenaar, D.T.; van de Sande, M.A.J.; van Langevelde, K. Wait-and-Scan: An Alternative for Curettage in Atypical Cartilaginous Tumours of the Long Bones. Bone Jt. J. 2024, 106-B, 86–92. [Google Scholar] [CrossRef] [PubMed]
- Omlor, G.W.; Lohnherr, V.; Lange, J.; Gantz, S.; Mechtersheimer, G.; Merle, C.; Raiss, P.; Fellenberg, J.; Lehner, B. Outcome of Conservative and Surgical Treatment of Enchondromas and Atypical Cartilaginous Tumors of the Long Bones: Retrospective Analysis of 228 Patients. BMC Musculoskelet. Disord. 2019, 20, 134. [Google Scholar] [CrossRef] [PubMed]
- Deckers, C.; de Rooy, J.W.J.; Flucke, U.; Schreuder, H.W.B.; Dierselhuis, E.F.; Geest, I.C.M. van der Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones. Cancers 2021, 13, 4093. [Google Scholar] [CrossRef] [PubMed]
- Parlier-Cuau, C.; Bousson, V.; Ogilvie, C.M.; Lackman, R.D.; Laredo, J.-D. When Should We Biopsy a Solitary Central Cartilaginous Tumor of Long Bones? Literature Review and Management Proposal. Eur. J. Radiol. 2011, 77, 6–12. [Google Scholar] [CrossRef]
- Deckers, C.; Schreuder, B.H.W.; Hannink, G.; de Rooy, J.W.J.; van der Geest, I.C.M. Radiologic Follow-up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones. J. Surg. Oncol. 2016, 114, 987–991. [Google Scholar] [CrossRef]
- Afonso, P.D.; Isaac, A.; Villagrán, J.M. Chondroid Tumors as Incidental Findings and Differential Diagnosis between Enchondromas and Low-Grade Chondrosarcomas. Semin. Musculoskelet. Radiol. 2019, 23, 3–18. [Google Scholar] [CrossRef]
- Herget, G.W.; Strohm, P.; Rottenburger, C.; Kontny, U.; Krauß, T.; Bohm, J.; Sudkamp, N.; Uhl, M. Insights into Enchondroma, Enchondromatosis and the Risk of Secondary Chondrosarcoma. Review of the Literature with an Emphasis on the Clinical Behaviour, Radiology, Malignant Transformation and the Follow Up. Neoplasma 2014, 61, 365–378. [Google Scholar] [CrossRef]
- Schwab, J.H.; Wenger, D.; Unni, K.; Sim, F.H. Does Local Recurrence Impact Survival in Low-Grade Chondrosarcoma of the Long Bones? Clin. Orthop. Relat. Res. 2007, 462, 175–180. [Google Scholar] [CrossRef] [PubMed]
- Andreou, D.; Gilg, M.M.; Gosheger, G.; Werner, M.; Hardes, J.; Pink, D.; Leithner, A.; Tunn, P.-U.; Streitbürger, A. Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-Institutional Study. Ann. Surg. Oncol. 2016, 23, 120–125. [Google Scholar] [CrossRef] [PubMed]
- Deckers, C.; Steyvers, M.J.; Hannink, G.; Schreuder, H.W.B.; de Rooy, J.W.J.; Van Der Geest, I.C.M. Can MRI Differentiate between Atypical Cartilaginous Tumors and High-Grade Chondrosarcoma? A Systematic Review. Acta. Orthop. 2020, 91, 471–478. [Google Scholar] [CrossRef] [PubMed]
- van Oosterwijk, J.G.; Meijer, D.; van Ruler, M.A.J.H.; van den Akker, B.E.W.M.; Oosting, J.; Krenács, T.; Picci, P.; Flanagan, A.M.; Liegl-Atzwanger, B.; Leithner, A.; et al. Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFβ as Potential Targets. Am. J. Pathol. 2013, 182, 1347–1356. [Google Scholar] [CrossRef] [PubMed]
- Tarpey, P.S.; Behjati, S.; Cooke, S.L.; Van Loo, P.; Wedge, D.C.; Pillay, N.; Marshall, J.; O’Meara, S.; Davies, H.; Nik-Zainal, S.; et al. Frequent Mutation of the Major Cartilage Collagen Gene COL2A1 in Chondrosarcoma. Nat. Genet. 2013, 45, 923–926. [Google Scholar] [CrossRef] [PubMed]
- Dobashi, Y.; Sugimura, H.; Sato, A.; Hirabayashi, T.; Kanda, H.; Kitagawa, T.; Kawaguchi, N.; Imamura, T.; Machinami, R. Possible Association of P53 Overexpression and Mutation with High-Grade Chondrosarcoma. Diagn. Mol. Pathol. 1993, 2, 257–263. [Google Scholar] [CrossRef] [PubMed]
- Bovée, J.V.M.G.; Hogendoorn, P.C.W.; Wunder, J.S.; Alman, B.A. Cartilage Tumours and Bone Development: Molecular Pathology and Possible Therapeutic Targets. Nat. Rev. Cancer 2010, 10, 481–488. [Google Scholar] [CrossRef]
- Schrage, Y.M.; Lam, S.; Jochemsen, A.G.; Cleton-Jansen, A.-M.; Taminiau, A.H.M.; Hogendoorn, P.C.W.; Bovée, J.V.M.G. Central Chondrosarcoma Progression Is Associated with pRb Pathway Alterations: CDK4 down-Regulation and P16 Overexpression Inhibit Cell Growth in Vitro. J. Cell Mol. Med. 2009, 13, 2843–2852. [Google Scholar] [CrossRef]
- Amary, M.F.; Ye, H.; Forbes, G.; Damato, S.; Maggiani, F.; Pollock, R.; Tirabosco, R.; Flanagan, A.M. Isocitrate Dehydrogenase 1 Mutations (IDH1) and P16/CDKN2A Copy Number Change in Conventional Chondrosarcomas. Virchows Arch. 2015, 466, 217–222. [Google Scholar] [CrossRef]
- Morrison, C.; Radmacher, M.; Mohammed, N.; Suster, D.; Auer, H.; Jones, S.; Riggenbach, J.; Kelbick, N.; Bos, G.; Mayerson, J. MYC Amplification and Polysomy 8 in Chondrosarcoma: Array Comparative Genomic Hybridization, Fluorescent in Situ Hybridization, and Association with Outcome. J. Clin. Oncol. 2005, 23, 9369–9376. [Google Scholar] [CrossRef]
- Schwab, J.H.; Boland, P.J.; Agaram, N.P.; Socci, N.D.; Guo, T.; O’Toole, G.C.; Wang, X.; Ostroumov, E.; Hunter, C.J.; Block, J.A.; et al. Chordoma and Chondrosarcoma Gene Profile: Implications for Immunotherapy. Cancer Immunol. Immunother. 2009, 58, 339–349. [Google Scholar] [CrossRef] [PubMed]
- Bovée, J.V.; Cleton-Jansen, A.M.; Kuipers-Dijkshoorn, N.J.; van den Broek, L.J.; Taminiau, A.H.; Cornelisse, C.J.; Hogendoorn, P.C. Loss of Heterozygosity and DNA Ploidy Point to a Diverging Genetic Mechanism in the Origin of Peripheral and Central Chondrosarcoma. Genes Chromosomes Cancer 1999, 26, 237–246. [Google Scholar] [CrossRef]
- de Andrea, C.E.; Reijnders, C.M.A.; Kroon, H.M.; de Jong, D.; Hogendoorn, P.C.W.; Szuhai, K.; Bovée, J.V.M.G. Secondary Peripheral Chondrosarcoma Evolving from Osteochondroma as a Result of Outgrowth of Cells with Functional EXT. Oncogene 2012, 31, 1095–1104. [Google Scholar] [CrossRef] [PubMed]
- Zhu, G.G.; Nafa, K.; Agaram, N.; Zehir, A.; Benayed, R.; Sadowska, J.; Borsu, L.; Kelly, C.; Tap, W.D.; Fabbri, N.; et al. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clin. Cancer Res. 2020, 26, 419–427. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chen, Y.; Yang, C.; Seger, N.; Hesla, A.C.; Tsagkozis, P.; Larsson, O.; Lin, Y.; Haglund, F. TERT Promoter Mutation Is an Objective Clinical Marker for Disease Progression in Chondrosarcoma. Mod. Pathol. 2021, 34, 2020–2027. [Google Scholar] [CrossRef] [PubMed]
- Bernstein-Molho, R.; Kollender, Y.; Issakov, J.; Bickels, J.; Dadia, S.; Flusser, G.; Meller, I.; Sagi-Eisenberg, R.; Merimsky, O. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother. Pharmacol. 2012, 70, 855–860. [Google Scholar] [CrossRef] [PubMed]
- Italiano, A.; Le Cesne, A.; Bellera, C.; Piperno-Neumann, S.; Duffaud, F.; Penel, N.; Cassier, P.; Domont, J.; Takebe, N.; Kind, M.; et al. GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann. Oncol. 2013, 24, 2922–2926. [Google Scholar] [CrossRef] [PubMed]
- Bupathi, M.; Hays, J.L.; Chen, J.L. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. PLoS ONE 2017, 12, e0188116. [Google Scholar] [CrossRef]
- Tap, W.D.; Villalobos, V.M.; Cote, G.M.; Burris, H.; Janku, F.; Mir, O.; Beeram, M.; Wagner, A.J.; Jiang, L.; Wu, B.; et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma. J. Clin. Oncol. 2020, 38, 1693–1701. [Google Scholar] [CrossRef]
- Kostine, M.; Cleven, A.H.; de Miranda, N.F.C.C.; Italiano, A.; Cleton-Jansen, A.M.; Bovée, J.V.M.G. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod. Pathol. 2016, 29, 1028–1037. [Google Scholar] [CrossRef]
- Iseulys, R.; Anne, G.B.; Corinne, B.; Gonzague, D.B.D.P.; Marie, K.; Jean-Yves, B.; Aurélie, D. The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target. J. Bone Oncol. 2020, 20, 100271. [Google Scholar] [CrossRef]
- Paoluzzi, L.; Cacavio, A.; Ghesani, M.; Karambelkar, A.; Rapkiewicz, A.; Weber, J.; Rosen, G. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin. Sarcoma Res. 2016, 6, 24. [Google Scholar] [CrossRef]
- Tawbi, H.A.; Burgess, M.; Bolejack, V.; Van Tine, B.A.; Schuetze, S.M.; Hu, J.; D’Angelo, S.; Attia, S.; Riedel, R.F.; Priebat, D.A.; et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017, 18, 1493–1501. [Google Scholar] [CrossRef]
- Singh, A.; Thorpe, S.W.; Darrow, M.; Carr-Ascher, J.R. Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response. Front. Oncol. 2022, 12, 991724. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tsukamoto, S.; Mavrogenis, A.F.; Nitta, Y.; Righi, A.; Masunaga, T.; Honoki, K.; Fujii, H.; Kido, A.; Tanaka, Y.; Tanaka, Y.; et al. A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma. Curr. Oncol. 2024, 31, 566-578. https://doi.org/10.3390/curroncol31010040
Tsukamoto S, Mavrogenis AF, Nitta Y, Righi A, Masunaga T, Honoki K, Fujii H, Kido A, Tanaka Y, Tanaka Y, et al. A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma. Current Oncology. 2024; 31(1):566-578. https://doi.org/10.3390/curroncol31010040
Chicago/Turabian StyleTsukamoto, Shinji, Andreas F. Mavrogenis, Yuji Nitta, Alberto Righi, Tomoya Masunaga, Kanya Honoki, Hiromasa Fujii, Akira Kido, Yuu Tanaka, Yasuhito Tanaka, and et al. 2024. "A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma" Current Oncology 31, no. 1: 566-578. https://doi.org/10.3390/curroncol31010040
APA StyleTsukamoto, S., Mavrogenis, A. F., Nitta, Y., Righi, A., Masunaga, T., Honoki, K., Fujii, H., Kido, A., Tanaka, Y., Tanaka, Y., & Errani, C. (2024). A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma. Current Oncology, 31(1), 566-578. https://doi.org/10.3390/curroncol31010040